Pharmaceuticals

Huntington’s Disease Treatment Industry Insights: Market Forecast to 2029

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Was The Huntington’s Disease Treatment Market Worth In 2025, And What Is Its Anticipated Value By 2029?

The Huntington’s disease treatment market size has experienced swift expansion in recent years. Forecasts indicate it will expand from $0.73 billion in 2024 to reach $0.82 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 12.3%. Historically, this market expansion can be ascribed to factors such as heightened awareness of genetic conditions, greater availability of genetic testing, increased funding for research into neurodegenerative diseases, a surge in clinical trials for experimental therapies, and an expanding selection of disease-modifying drug candidates.

The Huntington’s disease treatment market size is projected to experience substantial expansion over the upcoming years, reaching $1.32 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 12.6%. This anticipated growth during the forecast period stems from factors such as an escalating emphasis on personalized medicine, greater integration of digital health monitoring, enhanced regulatory backing for orphan drugs, increasing demand for therapies aimed at symptomatic relief, and a rising need for disease-modifying treatments. Key developments expected within this period encompass technology-driven gene silencing tools, the advancement of cell-based therapies, the emergence of peripheral biomarkers, the incorporation of telehealth into HD care, the integration of patient-reported outcomes, and ongoing innovation in disease-modifying drugs.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24245&type=smp

Which Factors And Drivers Are Influencing The Huntington’s Disease Treatment Market In 2025?

The expanding availability of gene therapies is anticipated to drive the future expansion of the Huntington’s disease treatment market. These therapies function by altering or substituting defective genes, aiming to remedy or avert conditions at their genetic origin. The development of gene therapies is progressing alongside advancements in precision medicine, allowing for precise targeting of genetic roots of diseases and yielding superior results compared to conventional approaches. For Huntington’s disease, gene therapies work by deactivating the flawed HTT gene responsible for producing detrimental proteins, thereby hindering nerve cell deterioration. This method contributes to decelerating the disease’s progression, safeguarding brain functionality, and presents a prospect for sustained management. An illustrative example, reported in July 2023 by the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, showed that while 247 gene therapies were in phase II at the close of Q1 2023, this figure saw a 5% increase, reaching 260 by the conclusion of Q2. Consequently, the proliferation of gene therapies is a significant impetus behind the expansion of the Huntington’s disease treatment market.

What Are The Different Segment Classifications Within The Huntington’s Disease Treatment Market?

The huntington’s disease treatment market covered in this report is segmented –

1) By Treatment: Symptomatic Treatment, Disease-Modifying Therapies

2) By Administration Type: Oral, Intravenous, Subcutaneous, Topical

3) By Therapeutic: Genetic Disorders, Neurological Disorders, Psychiatric Disorders

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Clinics, Homecare Settings, Research Centers

Subsegments:

1) By Symptomatic Treatment: Antidepressants, Antipsychotics, Mood Stabilizers, Chorea Medications, Cognitive Enhancers

2) By Disease-Modifying Therapies: Gene Therapy, Neuroprotective Agents, RNA-Based Therapies, Stem Cell Therapy, Protein-Targeting Therapies

Which Ongoing Trends Are Expected To Shape The Huntington’s Disease Treatment Market Outlook?

Leading firms within the Huntington’s disease treatment market are concentrating on creating cutting-edge therapies, like selective vesicular monoamine transporter 2 (VMAT2) inhibitor capsules, with the aim of enhancing patients’ quality of life and decelerating the illness’s advancement. These selective VMAT2 inhibitor capsules function as drugs that impede vesicular monoamine transporter 2, which is a protein crucial for the packaging of neurotransmitters prior to their release in the brain. By reducing neurotransmitter release, these medications assist in controlling involuntary movements and associated symptoms. As an example, in August 2023, Neurocrine Biosciences, Inc., a US-based biotech company, obtained approval from the U.S. Food and Drug Administration (FDA) for Ingrezza (valbenazine) capsules, intended for treating chorea linked to Huntington’s disease (HD) in adults. These capsules represent a once-daily oral VMAT2 inhibitor that functions by diminishing overactive dopamine signaling in the brain, thereby assisting in the management of involuntary movements. This medication is offered in multiple capsule strengths and can be administered with or without food, providing a practical dosing choice for patients.

Which Key Players Are Driving Competition In The Huntington’s Disease Treatment Market?

Major companies operating in the huntington’s disease treatment market are F. Hoffmann-La Roche Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Bausch Health Companies Inc., Sun Pharmaceutical Industries Inc., H. Lundbeck A/S, WaVe Life Sciences Ltd., Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals plc, Lupin Limited, Neurocrine Biosciences Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Annexon Inc., Uniqure NV, Sage Therapeutics Inc., Azevan Pharmaceuticals Inc., Prilenia Therapeutics B.V.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/huntingtons-disease-treatment-global-market-report

What Are The Key Regional Factors Influencing The Huntington’s Disease Treatment Market Growth?

North America was the largest region in the Huntington’s disease treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the huntington’s disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Huntington’s Disease Treatment Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24245&type=smp

Browse Through More Reports Similar to the Global Huntington’s Disease Treatment Market 2025, By The Business Research Company

Brain Tumor Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market-report

Brain And Neuroimaging Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/brain-and-neuroimaging-devices-global-market-report

Brain Tumor Drugs Global Market 2025

https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795